Victory Capital Management
GNCA

Victory Capital Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

Victory Capital Management’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,512
Closed -$12K – 3749
2020
Q1 		$12K Buy
+6,512
New +$13.2K ﹤0.01% 3283
2019
Q4 		– Sell
-3,183
Closed -$9K – 3772
2019
Q3 		$9K Buy
+3,183
New +$10.9K ﹤0.01% 3318

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Victory Capital Management's GNCA Position: Q2 2020 in Review

Victory Capital Management sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2020, closing a stake of 6,512 shares — an estimated $12K sold.

Victory Capital Management first reported a position in GNCA in Q3 2019 and held it in 2 quarters. The position peaked at $12K in Q1 2020. 35 funds tracked by Wall St. Rank hold GNCA as of Q2 2020.

  • Victory Capital Management reported no remaining Genocea Biosciences, Inc. position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 6,512 Genocea Biosciences, Inc. shares in Q2 2020, an estimated $12K.
  • Victory Capital Management first reported a position in Genocea Biosciences, Inc. in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Genocea Biosciences, Inc. position peaked at $12K in Q1 2020.
  • 35 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.